William R. Ringo Sells 500 Shares of Five Prime Therapeutics Inc. (FPRX) Stock
Five Prime Therapeutics Inc. (NASDAQ:FPRX) Director William R. Ringo sold 500 shares of the firm’s stock in a transaction that occurred on Monday, October 3rd. The shares were sold at an average price of $52.00, for a total transaction of $26,000.00. Following the completion of the transaction, the director now owns 500 shares of the company’s stock, valued at approximately $26,000. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.
Shares of Five Prime Therapeutics Inc. (NASDAQ:FPRX) opened at 52.48 on Wednesday. Five Prime Therapeutics Inc. has a 52-week low of $15.13 and a 52-week high of $55.00. The firm has a market cap of $1.41 billion, a P/E ratio of 5.90 and a beta of 4.46. The firm’s 50-day moving average is $48.77 and its 200-day moving average is $45.30.
Five Prime Therapeutics (NASDAQ:FPRX) last announced its quarterly earnings data on Thursday, August 4th. The company reported ($0.49) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.56) by $0.07. Five Prime Therapeutics had a return on equity of 69.59% and a net margin of 63.88%. The firm earned $9.23 million during the quarter, compared to the consensus estimate of $6.38 million. During the same quarter in the previous year, the company posted ($0.45) earnings per share. The business’s revenue was up 46.1% on a year-over-year basis. Analysts anticipate that Five Prime Therapeutics Inc. will post ($2.37) earnings per share for the current year.
FPRX has been the subject of a number of research reports. Jefferies Group set a $60.00 price objective on shares of Five Prime Therapeutics and gave the company a “buy” rating in a report on Friday, August 5th. Leerink Swann reissued a “buy” rating and set a $45.00 target price on shares of Five Prime Therapeutics in a research report on Friday, July 15th. Finally, Credit Suisse Group AG reissued a “buy” rating on shares of Five Prime Therapeutics in a research report on Tuesday, July 12th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $52.33.
A number of hedge funds have recently made changes to their positions in FPRX. Teacher Retirement System of Texas increased its stake in shares of Five Prime Therapeutics by 37.4% in the second quarter. Teacher Retirement System of Texas now owns 3,495 shares of the company’s stock valued at $145,000 after buying an additional 951 shares during the last quarter. Legal & General Group Plc increased its position in shares of Five Prime Therapeutics by 15.8% in the first quarter. Legal & General Group Plc now owns 3,869 shares of the company’s stock worth $160,000 after buying an additional 527 shares in the last quarter. Acrospire Investment Management LLC increased its position in shares of Five Prime Therapeutics by 200.0% in the second quarter. Acrospire Investment Management LLC now owns 4,800 shares of the company’s stock worth $198,000 after buying an additional 3,200 shares in the last quarter. Analytic Investors LLC acquired a new position in shares of Five Prime Therapeutics during the second quarter worth approximately $200,000. Finally, Williams Jones & Associates LLC acquired a new position in shares of Five Prime Therapeutics during the first quarter worth approximately $240,000. Hedge funds and other institutional investors own 86.49% of the company’s stock.
Five Prime Therapeutics Company Profile
Five Prime Therapeutics, Inc (Five Prime) is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company has three product candidates in clinical development covering multiple potential indications. It focuses on immuno-oncology, an area in which it has clinical and discovery programs, and product and discovery collaborations.
Receive News & Stock Ratings for Five Prime Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics Inc. and related stocks with our FREE daily email newsletter.